Is Bromhexine registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 7 valid registrations of Bromhexine, including BISOLVON 8MG TABLETS (8 mg, Tablet, SAR 11.90); EZOLVIN 4MG\5ML SYRUP (0.8 mg/ml, Syrup, SAR 7.60); EZOLVIN 8MGTAB (8 mg, Tablet, SAR 8.85); MUCOFREE 4MG-5ML SYRUP (0.8 mg/ml, Syrup, SAR 4.85); MUCOLYTE SYRUP (0.8 mg/ml, Syrup, SAR 6.20).

Active substance

Bromhexine

SFDA 10

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
BISOLVON 8MG TABLETS	8 mg	Tablet · Oral use	20 Blister	SAR 11.90	Generic · OTC	BOEHRINGER INGELHEIM	Valid
EZOLVIN 4MG\5ML SYRUP	0.8 mg/ml	Syrup · Oral use	1 Bottle	SAR 7.60	Generic · OTC	KUWAIT SAUDI PHARMACEUTICAL INDUSTRIES	Valid
EZOLVIN 8MGTAB	8 mg	Tablet · Oral use	20 Blister	SAR 8.85	Generic · OTC	KUWAIT SAUDI PHARMACEUTICAL INDUSTRIES	Valid
MUCOFREE 4MG-5ML SYRUP	0.8 mg/ml	Syrup · Oral use	1 Bottle	SAR 4.85	Generic · OTC	JORDAN RIVER PHARMACEUTICAL INDUSTRIES	Valid
MUCOLYTE SYRUP	0.8 mg/ml	Syrup · Oral use	1 Bottle	SAR 6.20	Generic · OTC	Gulf Pharmaceutical Industries (Julphar)	Valid
RIAXINE	0.8 mg/ml	Oral solution · Oral use	1 Bottle	SAR 9.00	Generic · OTC	RIYADH PHARMA	Valid
SOLVEX 4MG-5ML SYRUP	0.8 mg/ml	Syrup · Oral use	1 Bottle	SAR 6.65	Generic · OTC	Jazeera Pharmaceutical Industries (JPI)	Valid
BISOLVON ELIXIR 4MG-5ML	0.8 mg/ml	Solution · Oral use	1 Bottle	SAR 11.45	NCE · OTC	BOEHRINGER INGELHEIM	Invalid · Not Marketed
PULMOTROPIC DROPS 2MG-ML	2 mg/ml	Solution · Oral use	1 Dropper Container	SAR 5.35	Generic · OTC	FERRER INTERNATIONAL	Withdrawn by MAH · Not Marketed
PULMOTROPIC ELIXIR 4MG-5ML	0.8 mg/ml	Syrup · Oral use	1 Bottle	SAR 8.10	Generic · OTC	FERRER INTERNATIONAL	Withdrawn by MAH · Not Marketed

Indications — CHI Daman Drug Formulary

ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS)-LONG-TERM ORAL ANTIBIOTIC TREATMENT-AIRWAY CLEARANCE

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.